Cancer Research and Treatment10.4143/crt.2016.2892017493569-577An Open-Label, Randomized, Parallel, Phase III Trial Evaluating the Efficacy and Safety of Polymeric Micelle-Formulated Paclitaxel Compared to Conventional Cremophor EL-Based Paclitaxel for Recurrent or Metastatic HER2-Negative Breast CancerIn Hae Park, Joo Hyuk Sohn, Sung Bae Kim, Keun Seok Lee, Joo Seop Chung, Soo Hyeon Lee, Tae You Kim, Kyung Hae Jung, Eun Kyung Cho, Yang Soo Kim, Hong Suk Song, Jae Hong Seo, Hun Mo Ryoo, Sun Ah Lee, So Young Yoon, Chul Soo Kim, Yong Tai Kim, Si Young Kim, Mi Ryung Jin, Jungsil Ro,,
Annals of Oncology10.1093/annonc/mdy428.009201829ix17Estimation of efficacy and safety of a Cremophor-free, polymeric micelle formulation of paclitaxel, in recurrent or metastatic breast cancer patientsS.S. Kang,,
Gynecologic Oncology10.1016/j.ygyno.2019.11.03420201562293-300A randomized phase III trial in patients with recurrent platinum sensitive ovarian cancer comparing efficacy and safety of paclitaxel micellar and Cremophor EL-paclitaxelI. Vergote, K. Bergfeldt, A. Franquet, A.S. Lisyanskaya, H. Bjermo, N. Heldring, M. Buyse, A. Brize,
Gynecologic Oncology10.1016/s0090-8258(21)01062-32021162S216Occupational safety of doxorubicin, cisplatin, paclitaxel, and cremophor-free polymeric micelle formulated paclitaxel during rotational intraperitoneal pressurized aerosol chemotherapySoo Jin Park, Hee Seung Kim, Jae-Weon Kim,
Cancer Research and Treatment10.4143/crt.2016.3762018501195-203An Open-Label, Randomized, Parallel, Phase II Trial to Evaluate the Efficacy and Safety of a Cremophor-Free Polymeric Micelle Formulation of Paclitaxel as First-Line Treatment for Ovarian Cancer: A Korean Gynecologic Oncology Group Study (KGOG-3021)Shin-Wha Lee, Yong-Man Kim, Chi Heum Cho, Young Tae Kim, Seok Mo Kim, Soo Young Hur, Jae-Hoon Kim, Byoung-Gie Kim, Seung-Cheol Kim, Hee-Sug Ryu, Soon Beom Kang,,
European Journal of Cancer10.1016/j.ejca.2017.10.018201890153-155Overall survival in MERiDiAN, a double-blind placebo-controlled randomised phase III trial evaluating first-line bevacizumab plus paclitaxel for HER2-negative metastatic breast cancerDavid Miles, David Cameron, Magalie Hilton, Josep Garcia, Joyce O'Shaughnessy,
Clinical Breast Cancer10.3816/cbc.2003.n.007200336421-422E2100: A Phase III Trial of Paclitaxel Versus Paclitaxel/Bevacizumab for Metastatic Breast CancerKathy D. Miller,
Breast Diseases: A Year Book Quarterly10.1016/s1043-321x(05)80058-x200516171-721–37 Multicenter Randomized Phase III Trial of Epirubicin Plus Paclitaxel vs Epirubicin Followed by Paclitaxel in Metastatic Breast Cancer Patients: Focus on Cardiac SafetyA.D. Seidman,
Breast Cancer Research and Treatment10.1007/s10549-007-9591-y20071082241-250Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancerKeun Seok Lee, Hyun Cheol Chung, Seock Ah Im, Yeon Hee Park, Chul Soo Kim, Sung-Bae Kim, Sun Young Rha, Min Young Lee, Jungsil Ro,,
Annals of Oncology10.1093/annonc/mdu436.77201425v75Bevacizumab Plus Paclitaxel for Her2 Negative Advanced/Recurrent Breast Cancer: Assessment of Efficacy and SafetyKenji Kunieda, Satomi Matsuo, Junichirou Watanabe,,